Nanobiotix Dirección

Dirección controles de criterios 1/4

El CEO de Nanobiotix es Laurent Levy , nombrado en Mar 2003, tiene una permanencia de 21.67 años. compensación anual total es €3.40M, compuesta por 12.1% salario y 87.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.4% de las acciones de la empresa, por valor de $4.15M. La antigüedad media del equipo directivo y de la junta directiva es de 5.3 años y 2 años, respectivamente.

Información clave

Laurent Levy

Chief Executive Officer (CEO)

€3.4m

Compensación total

Porcentaje del salario del CEO	12.1%
Permanencia del CEO	21.7yrs
Participación del CEO	2.4%
Permanencia media de la dirección	5.3yrs
Promedio de permanencia en la Junta Directiva	2yrs

Actualizaciones recientes de la dirección

Recent updates

Nanobiotix enters final agreement to restructure existing loan with EU's investment bank

Oct 18

Nanobiotix GAAP EPS of -€0.76, revenue of €1.33M beats by €0.11M

Sep 28

Nanobiotix agrees in principle to restructure debt obligations with EU's investment bank

Sep 12

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Laurent Levy en comparación con los beneficios de Nanobiotix?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-€33m
Mar 31 2024	n/a	n/a	-€37m
Dec 31 2023	€3m	€411k	-€40m
Sep 30 2023	n/a	n/a	-€49m
Jun 30 2023	n/a	n/a	-€59m
Mar 31 2023	n/a	n/a	-€58m
Dec 31 2022	€1m	€380k	-€57m
Sep 30 2022	n/a	n/a	-€50m
Jun 30 2022	n/a	n/a	-€43m
Mar 31 2022	n/a	n/a	-€45m
Dec 31 2021	€4m	€380k	-€47m
Sep 30 2021	n/a	n/a	-€45m
Jun 30 2021	n/a	n/a	-€43m
Mar 31 2021	n/a	n/a	-€39m
Dec 31 2020	€818k	€330k	-€34m
Sep 30 2020	n/a	n/a	-€41m
Jun 30 2020	n/a	n/a	-€48m
Mar 31 2020	n/a	n/a	-€49m
Dec 31 2019	€2m	€330k	-€51m
Sep 30 2019	n/a	n/a	-€46m
Jun 30 2019	n/a	n/a	-€42m
Mar 31 2019	n/a	n/a	-€36m
Dec 31 2018	€1m	€300k	-€30m
Sep 30 2018	n/a	n/a	-€28m
Jun 30 2018	n/a	n/a	-€27m
Mar 31 2018	n/a	n/a	-€26m
Dec 31 2017	€861k	€253k	-€26m

Compensación vs. Mercado: La compensación total de Laurent($USD3.54M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.46M).

Compensación vs. Ingresos: La compensación de Laurent ha aumentado mientras la empresa no es rentable.

CEO

Laurent Levy (51 yo)

21.7yrs

Permanencia

€3,396,084

Compensación

Mr. Laurent Lévy, Ph.D. has been the President of the Executive Board at Nanobiotix S.A. since May 27, 2004 and its Chief Executive Officer since March 2003. Mr. Lévy has a thorough understanding of the te...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Laurent Levy	Co-Founder	21.7yrs	€3.40m	2.4% $ 4.2m
Bart Van Rhijn	Chief Financial & Business Officer and Member of Executive Board	3.4yrs	€1.50m	0% $ 0
Anne-Juliette Hermant	Chief People Officer & Member of Executive Board	5.3yrs	€801.96k	0.30% $ 510.3k
Louis Kayitalire	Chief Medical Officer	1.2yrs	€500.80k	sin datos
Earl Bergey	Co-Founder	21.8yrs	sin datos	sin datos
Craig West	Senior Vice President of Investor Relations	no data	sin datos	sin datos
Brandon Owens	VP of Strategic Marketing & Corporate Communication	no data	sin datos	sin datos
Margaret Galluzzi	VP & Global Head of Clinical Operations	5.8yrs	sin datos	sin datos
Leonard Farber	Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board	2.8yrs	sin datos	sin datos

5.3yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de NBTX es experimentado (5.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Leonard Farber	Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board	no data	sin datos	sin datos
Enno Spillner	Independent Member of Supervisory Board	10.4yrs	€50.00k	sin datos
Gary Phillips	Independent Chairman of Supervisory board	3.5yrs	€63.00k	sin datos
Silvia Formenti	Member of Scientific Advisory Board	2yrs	sin datos	sin datos
Alain Herrera	Independent Member of Supervisory Board	11.4yrs	€35.00k	sin datos
Anne-Marie Graffin	Independent Vice Chairman of the Supervisory Board	10.9yrs	€42.00k	sin datos
Hisham Mehanna	Member of Scientific Advisory Board	2yrs	sin datos	sin datos
Stephane Champiat	Member of Scientific Advisory Board	2yrs	sin datos	sin datos
Jean Bourhis	Member of Scientific Advisory Board	2yrs	sin datos	sin datos
Thierry Baere	Member of Scientific Advisory Board	2yrs	sin datos	sin datos
Christophe Tourneau	Member of Scientific Advisory Board	2yrs	sin datos	sin datos
Nancy Lee	Member of Scientific Advisory Board	2yrs	sin datos	sin datos

2.0yrs

Permanencia media

60.5yo

Promedio de edad

Junta con experiencia: La junta directiva de NBTX no se considera experimentada (2 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Nanobiotix Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

Recent updates

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

Nanobiotix S.A. to Report Q1, 2024 Results on May 22, 2024

Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer

Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024

Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $29.288592 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of $30 million.

Nanobiotix S.A. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. Announces Updated Preliminary Results from Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis from Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Nanobiotix S.A. Announces New Clinical Data from Phase 1 Study Evaluating Radiotherapy-Activated Nbtxr3 for Patients with Pancreatic Ductal Adenocarcinoma

Nanobiotix S.A. to Report First Half, 2023 Results on Sep 26, 2023

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

Nanobiotix S.A. Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

NANOBIOTIX Announces First Patient Randomized in United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

NANOBIOTIX Recommends Phase 2 Dose for NBTXR3 in Pancreatic Cancer

NANOBIOTIX Updates Data from its Phase 1 Immunotherapy Study, Study 1100

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

Nanobiotix enters final agreement to restructure existing loan with EU's investment bank

Nanobiotix GAAP EPS of -€0.76, revenue of €1.33M beats by €0.11M

NANOBIOTIX Establishes Recommends Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

Nanobiotix agrees in principle to restructure debt obligations with EU's investment bank

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

French biotech Nanobiotix rebounds to post best ever 47% intraday gain

NANOBIOTIX Announces the Reporting of New Data at the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces the Reporting of New Data At the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. to Report First Half, 2022 Results on Sep 28, 2022

Nanobiotix S.A. Announces New Data from an Open-Label Preclinical Study Evaluating the Combination of First-in-Class Radioenhancer, NBTXR3, with the Triple Blockade of PD-1, LAG-3, and TIGIT

Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer

Nanobiotix S.A. Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4

Nanobiotix S.A. Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer

Nanobiotix S.A. Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May 'Reprogram' the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect

NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure

Nanobiotix names Bart Van Rhijn as chief financial officer

Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces New Data from its Oncology Pipeline to Be Present at the 2021 American Society of Clinical Oncology Annual Meeting

NANOBIOTIX and PharmaEngine, Inc. Mutually Agree to Conclude Collaboration

NANOBIOTIX Announces Positive New Preclinical Data Investigating First-In-Class Radioenhancer NBTXR3

Nanobiotix S.A. to Report Q2, 2021 Results on Sep 03, 2021

Nanobiotix Announces First Patient Injected with NBTXR3 in Esophageal Cancer

Nanobiotix Will Disrupt Oncological Radiotherapy

NANOBIOTIX Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad